Literature DB >> 9855502

Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease.

M A Lovell1, C Xie, W R Markesbery.   

Abstract

OBJECTIVE: To investigate the levels of glutathione transferase (GST), a protective enzyme against aldehydes, and especially 4-hydroxynonenal (HNE) in the brain and ventricular CSF of autopsied AD and normal control subjects.
BACKGROUND: Studies have implicated increased levels of oxidative stress in the brain in the pathogenesis of AD. Decreased levels of polyunsaturated fatty acids and increased levels of markers of lipid peroxidation have been reported in the brain in AD, particularly in areas severely affected in the disease. HNE, one marker of lipid peroxidation, is neurotoxic in neuronal culture and in vivo and is elevated in AD brain and CSF.
METHODS: We measured levels of GST activity and protein in multiple brain regions and ventricular CSF in short-postmortem-interval AD patients and age-matched prospectively evaluated control subjects.
RESULTS: A decrease in GST activity in all brain areas was observed in AD compared with controls with significant decreases in the amygdala, hippocampus and parahippocampal gyrus, inferior parietal lobule, and nucleus basalis of Meynert. Levels of GST protein also were depleted in most brain regions in AD. A significant decrease in GST activity and protein levels was also found in ventricular CSF in AD.
CONCLUSION: Reduced levels of GST, a protective mechanism against HNE, may have a role in the pathogenesis of neuron degeneration in AD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855502     DOI: 10.1212/wnl.51.6.1562

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  68 in total

Review 1.  Protective effects of phenelzine administration on synaptic and non-synaptic cortical mitochondrial function and lipid peroxidation-mediated oxidative damage following TBI in young adult male rats.

Authors:  Rachel L Hill; Indrapal N Singh; Juan A Wang; Jacqueline R Kulbe; Edward D Hall
Journal:  Exp Neurol       Date:  2020-04-20       Impact factor: 5.330

2.  Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease.

Authors:  M A Bradley; W R Markesbery; M A Lovell
Journal:  Free Radic Biol Med       Date:  2010-02-18       Impact factor: 7.376

Review 3.  Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.

Authors:  D Allan Butterfield; Miranda L Bader Lange; Rukhsana Sultana
Journal:  Biochim Biophys Acta       Date:  2010-02-20

Review 4.  Oxidative imbalance in Alzheimer's disease.

Authors:  Xiongwei Zhu; Hyoung-Gon Lee; Gemma Casadesus; Jesus Avila; Kelly Drew; George Perry; Mark A Smith
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

5.  Expression of Nrf2 in neurodegenerative diseases.

Authors:  Chenere P Ramsey; Charles A Glass; Marshall B Montgomery; Kathryn A Lindl; Gillian P Ritson; Luis A Chia; Ronald L Hamilton; Charleen T Chu; Kelly L Jordan-Sciutto
Journal:  J Neuropathol Exp Neurol       Date:  2007-01       Impact factor: 3.685

Review 6.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

Review 7.  Elevation of glutathione as a therapeutic strategy in Alzheimer disease.

Authors:  Chava B Pocernich; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2011-10-12

Review 8.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

9.  Effects of Phenelzine Administration on Mitochondrial Function, Calcium Handling, and Cytoskeletal Degradation after Experimental Traumatic Brain Injury.

Authors:  Rachel L Hill; Indrapal N Singh; Juan A Wang; Edward D Hall
Journal:  J Neurotrauma       Date:  2018-12-12       Impact factor: 5.269

Review 10.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.